Lysine

Lysine

SCHEMBL6130146

C[C@@H](O)[C@H](N)C(=O)O.C[C@H](N)C(=O)O.NCCCC[C@H](N)C(=O)O

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.67
ARG2 P78540 4/20 0.43
ARG1 P05089 3/20 0.43
NOS2 P35228 5/20 0.42
NOS1 P29475 4/20 0.42
NOS3 P29474 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
RNPEP Q9H4A4 1/20 0.42
BLM P54132 1/20 0.41
MEN1 O00255 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
THRB P10828 1/20 0.40
GNAI3 P08754 1/20 0.39
GNAO1 P09471 1/20 0.39
GNAI1 P63096 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lysine SCHEMBL746845 0.97 GSR (0.71) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL21816467 0.97 GSR (0.71) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL1537438 0.97 GSR (0.71) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL3358270 0.97 GSR (0.71) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL746846 0.97 GSR (0.71) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL5084119 0.97 GSR (0.71) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL1537434 0.97 GSR (0.71) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL23292473 0.92 GSR (0.65) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL15674546 0.92 GSR (0.65) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL8322630 0.92 GSR (0.65) GSRARG2ARG1NOS2NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11939608-B2 Engineered heme-binding compositions and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2024-03-26 US claimed
US-11312949-B2 Engineered heme-binding compositions and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-04-26 US claimed
US-20220056089-A1 ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-02-24 US claimed
US-11059873-B2 Engineered opsonin for pathogen detection and treatment PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-07-13 US claimed
US-11059874-B2 Engineered opsonin for pathogen detection and treatment PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-07-13 US claimed
EP-3773461-A1 ENGINEERED TREATMENTS FOR HAIR REPAIR AND LONG-LASTING COLOR RETENTION Massachusetts Institute of Technology (US) 2021-02-17 EP claimed
CN-112118826-A Engineered treatments for hair restoration and long lasting color maintenance 麻省理工学院 2020-12-22 CN claimed
US-20200291083-A1 ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2020-09-17 US claimed
US-20200095300-A1 ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2020-03-26 US claimed
US-20190314260-A1 ENGINEERED TREATMENTS FOR HAIR REPAIR AND LONG-LASTING COLOR RETENTION MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2019-10-17 US claimed
WO-2019200233-A1 ENGINEERED TREATMENTS FOR HAIR REPAIR AND LONG-LASTING COLOR RETENTION MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2019-10-17 WO claimed
CN-102947341-B Engineered opsonins for pathogen detection and treatment 哈佛大学校长及研究员协会 2018-07-06 CN claimed
US-20180094035-A1 ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2018-04-05 US claimed
US-9834597-B2 Modified FC polypeptides, FC conjugates, and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-12-05 US claimed
US-20160200785-A1 ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2016-07-14 US claimed
US-9150631-B2 Engineered opsonin for pathogen detection and treatment PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-10-06 US claimed
US-20150218258-A1 MODIFIED FC POLYPEPTIDES, FC CONJUGATES, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-08-06 US claimed
US-11939608-B2 Engineered heme-binding compositions and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2024-03-26 US disclosed
WO-2002018438-A9 MODIFIED PROTEINS, ISOLATED NOVEL PEPTIDES, AND USES THEREOF UNIV AUSTRALIAN (AU) 2002-05-30 WO disclosed
WO-2002018438-A1 MODIFIED PROTEINS, ISOLATED NOVEL PEPTIDES, AND USES THEREOF THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939608-B2 Engineered heme-binding compositions and uses thereof MB, MYOF, HMBS GSR 518/4885ARG2 119/4885ARG1 623/4885
US-20150218258-A1 MODIFIED FC POLYPEPTIDES, FC CONJUGATES, AND METHODS OF USE THEREOF FCGR3B, FCGR2A, FCGR1A GSR 3579/4885ARG2 2600/4885ARG1 1859/4885
US-20190314260-A1 ENGINEERED TREATMENTS FOR HAIR REPAIR AND LONG-LASTING COLOR RETENTION KRT18, CD44, EPCAM GSR 462/4885ARG2 948/4885ARG1 751/4885
US-11312949-B2 Engineered heme-binding compositions and uses thereof MB, MYOF, HMBS GSR 518/4885ARG2 119/4885ARG1 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.